The Drug Producer is to submit the vaccine’s phase III trials data to DCGI next month.
Paris: On Saturday, fresh ambitions blossomed in Paris as Dr Krishna Ella declared that Bharat Biotech completed the phase III trial of its new Covid-19 nasal vaccine.
Ella, Chairman and Managing Director of the drug producer, added that the organization will submit its data to the Drug Controller General (DCGI) of India next month.
He added to sources earlier this week, “We just completed a clinical trial; data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, we will get permission to launch, and it will be the world’s first clinically proven nasal COVID-19 vaccine.”
Bharat Biotech will be all set to launch the world’s first nasal Covid-19 vaccine if the authorities approve the data.
The nasal vaccine will be a booster dose, said Dr Ella to those who had taken the second dose.
“Booster dose of vaccine gives immunity. I always say the booster dose is a miracle dose for every vaccination. Even in children first, two doses don’t give much immunity, but the third dose gives an amazing response to the child. The same thing for adults also. The third dose is very important for adults. COVID-19 can’t be eradicated 100 percent. It will be there and we have to live with it and handle it and more intelligently how to control it,” he added.
Dr Krishna Ella of Bharat Biotech announced the fresh news at the Viva Technology 2022 in Paris, where India was announced ‘the country of the year.’
VivaTech is a European start-up, and tech event held to celebrate fresh innovations and discoveries by start-ups across the world.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
